Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2009; 102(03): 606-608
DOI: 10.1160/TH09-02-0114
DOI: 10.1160/TH09-02-0114
Letters to the Editor
PPACK-Desmodus rotundus salivary plasminogen activator (cDSPAα1) prevents the passage of tissuetype plasminogen activator (rt-PA) across the blood-brain barrier and neurotoxicity
Authors
Financial support: This study was supported in part by research funding from PAION Deutschland GmbH.
Further Information
Publication History
Received:
23 February 2009
Accepted after major revision:
23 June 2009
Publication Date:
22 November 2017 (online)
* These authors contributed equally to this work.
-
References
- 1 NINDS. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study GroupTissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333: 1581-1587.
- 2 Tsirka SE, Gualandris A, Amaral DG. et al. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377: 340-344.
- 3 Nicole O, Docagne F, Ali C. et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 07: 59-64.
- 4 Schleuning WD, Alagon A, Boidol W. et al. Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity. Ann NY Acad Sci 1992; 04: 395-403.
- 5 Reddrop C, Moldrich RX, Beart PM. et al. Vampire bat salivary plasminogen activator (desmoteplase) in-hibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005; 36: 1241-1246.
- 6 López-Atalaya JP, Roussel BD, Ali C. et al. Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a lowdensity lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. Stroke 2007; 38: 1036-1043.
- 7 Cecchelli R, Dehouck B, Descamps L. et al. In vitro model for evaluating drug transport across the bloodbrain barrier. Adv Drug Deliv Rev 1999; 136: 165-178.
- 8 Benchenane K, Berezowski V, Ali C. et al. Tissuetype plasminogen activator crosses the intact bloodbrain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 2005; 111: 2241-2249.
- 9 Hacke W, Albers G, Al-Rawi Y. et al. DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73.
- 10 Hacke W, Furlan AJ, Al-Rawi Y. et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 08: 141-150.
- 11 Warach S. for the DIAS-2 Study Group. Clinical benefit of desmoteplase treatment in patients with moderate to severe stroke—further results of the DIAS-2 Study. Abstract presented at the International Stroke Conference; New Orleans; February. 21. 2008